Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Table 1 Study design

Study	Group	Vaccine	HA dose	Schedule
Study in adults	D-Pan	A/California/7/2009 (H1N1)v-like + AS03_A	3.75 μg	2 doses
18-60 year olds	Q-Pan	A/California/7/2009 (H1N1)v-like + AS03_A	3.75 μg	2 doses
Study in children	D-Pan0.9	A/California/7/2009 (H1N1)v-like + AS03_B	0.9 μg	1 dose
3-9 year olds	Q-Pan0.9	A/California/7/2009 (H1N1)v-like + AS03_B	0.9 μg	1 dose
	Q-Pan1.9	A/California/7/2009 (H1N1)v-like + AS03_B	1.9 μg	1 dose

HA haemagglutinin antigen, AS03 an oil-in-water emulsion containing DL-α-tocopherol and squalene in an aqueous phase with the non-ionic detergent polysorbate80. AS03_A contains 11.86 mg DL-α-tocopherolper dose; AS03_B contains 5.93 mg DL-α-tocopherol per dose.

ISSN: 1471-2334